Vermeire A, De Muynck C, Vandenbossche G, Eechaute W, Geerts M L, Remon J P
Laboratory of Pharmaceutical Technology, University of Gent, Belgium.
J Pharm Pharmacol. 1996 May;48(5):463-7. doi: 10.1111/j.2042-7158.1996.tb05955.x.
In this study sucrose laurate was formulated in hydrogels and investigated as a suitable transdermal penetration enhancer for oestradiol. Using rabbits as an animal model, the absolute bioavailability and the skin irritation were evaluated after single and multiple application. Three hydrogels containing 60 mg% oestradiol were evaluated: Oestrogel, and two hypromellose gels containing 5 and 15% sucrose laurate (w/w), respectively. No stability problem of the sucrose laurate was detected during a storage period of four months at 7 +/- 2 degrees C. After single application no significant difference (P < 0.05) was observed between the bioavailability parameters of Oestrogel and the 5% sucrose laurate gel. The values obtained for the 15% sucrose laurate gel were significantly higher than for the other gels. When applied on day 7 after a 6-day treatment, twice daily with the respective placebo gel, no significant difference was seen amongst the three formulations for any of the parameters evaluated. When the results after multiple application were compared with those after single application, a significant increase in oestradiol bioavailability was seen for the gel containing 30% ethanol and a significant decrease in oestradiol bioavailability was seen for the 5 and 15% sucrose laurate gels. Histological evaluation of the untreated and treated skin biopsies, showed a significantly higher incidence of infiltrate for all treated skin biopsies in comparison with the untreated ones. A significant increase in skinfold thickness was seen for the skin biopsies treated with gel containing 15% sucrose laurate. It can be concluded that sucrose laurate shows a potential as an absorption enhancer for percutaneous drug delivery.
在本研究中,月桂酸蔗糖酯被制成水凝胶,并作为雌二醇合适的透皮渗透促进剂进行研究。以兔子为动物模型,在单次和多次应用后评估其绝对生物利用度和皮肤刺激性。评估了三种含60mg%雌二醇的水凝胶:欧维婷凝胶,以及两种分别含5%和15%(w/w)月桂酸蔗糖酯的羟丙甲纤维素凝胶。在7±2℃的储存期四个月内未检测到月桂酸蔗糖酯的稳定性问题。单次应用后,欧维婷凝胶和5%月桂酸蔗糖酯凝胶的生物利用度参数之间未观察到显著差异(P<0.05)。15%月桂酸蔗糖酯凝胶获得的值显著高于其他凝胶。在分别用相应的安慰剂凝胶每日两次治疗6天后,于第7天应用时,三种制剂在任何评估参数之间均未观察到显著差异。当将多次应用后的结果与单次应用后的结果进行比较时,含30%乙醇的凝胶的雌二醇生物利用度显著增加,而5%和15%月桂酸蔗糖酯凝胶的雌二醇生物利用度显著降低。未处理和处理过的皮肤活检组织的组织学评估显示,与未处理的相比,所有处理过的皮肤活检组织中浸润发生率显著更高。用含15%月桂酸蔗糖酯的凝胶处理的皮肤活检组织的皮褶厚度显著增加。可以得出结论,月桂酸蔗糖酯显示出作为经皮给药吸收促进剂的潜力。